Why is Balaxi Pharma falling/rising?

As of 18-Sep, Balaxi Pharmaceuticals Ltd is currently priced at 46.04, reflecting a decrease of 0.16 or 0.35%. The stock has underperformed its sector today by 0.68%, with its delivery volume falling significantly by 37.48% compared to the 5-day average. Over the past week, the stock has shown a modest gain of 2.38%, but it has struggled over the longer term, with a 4.04% decline over the past month and a staggering 58.70% drop over the past year. The company's fundamentals indicate strong long-term potential, with an average Return on Equity (ROE) of 30.97% and a favorable valuation at a Price to Book Value of 1.1. However, negative financial results reported for June 25, including a 70.93% decline in profit before tax and a 95.5% drop in profit after tax, have contributed to the stock's recent struggles.
In the broader market context, Balaxi Pharmaceuticals has consistently underperformed against the benchmark, with a 1-year return of -58.70% compared to a slight gain of 0.18% for the Sensex. This underperformance is compounded by a decline in institutional investor participation, which has decreased by 7.16% over the previous quarter, indicating a lack of confidence from more knowledgeable market players. While the stock has shown some short-term resilience, the long-term trends and recent negative financial results suggest ongoing challenges that are likely influencing its current price movement.